Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease
- PMID: 15337615
- DOI: 10.1016/j.jns.2004.05.002
Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease
Abstract
To determine changes in signal transduction from the muscarinic acetylcholine receptor (mAChR) to G protein in brain tissue of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD), we investigated GTP-sensitive agonist high affinity binding, which is considered an index of the formation of the mAChR-G protein complex. Brain tissue was obtained at necropsy from eight patients with DLB, nine patients with Alzheimer's disease and seven patients as controls. Membrane fractions were prepared from frontal and temporal cerebral tissues. Displacement curves of [(3)H]l-quinuclidinyl benzilate (QNB) binding by carbamylcholine were analyzed by the nonlinear least-squares methods. The proportion of and affinity for the agonist in GTP-sensitive agonist high affinity binding were estimated. The percentages GTP-sensitive agonist high affinity bindings were significantly decreased in DLB (P<0.01) and Alzheimer's disease (P<0.05) only in the frontal lobe. There were no significant differences in the temporal lobe. The ratio of agonist affinity (Kd value of low affinity component/Kd value of high affinity component) did not significantly differ among groups in either the frontal lobe or temporal lobe. The concentration of mAChR-G protein complex is considered reduced in the frontal lobe of brains with DLB and Alzheimer's disease. Therefore, signal transduction from mAChR to G protein was disturbed in the frontal lobe in these diseases.
Similar articles
-
Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations.Exp Neurol. 1999 Aug;158(2):451-8. doi: 10.1006/exnr.1999.7116. Exp Neurol. 1999. PMID: 10415152
-
Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters.Synapse. 2003 Jan;47(1):58-65. doi: 10.1002/syn.10153. Synapse. 2003. PMID: 12422374
-
Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies.Ann Neurol. 1991 Mar;29(3):256-62. doi: 10.1002/ana.410290305. Ann Neurol. 1991. PMID: 2042942
-
Possible muscarinic supersensitivity in Alzheimer's disease.Prog Clin Biol Res. 1989;317:1223-33. Prog Clin Biol Res. 1989. PMID: 2690092 Review.
-
Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease.Trends Pharmacol Sci. 1989 Dec;Suppl:80-4. Trends Pharmacol Sci. 1989. PMID: 2694529 Review.
Cited by
-
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.Acta Neuropathol. 2011 Jul;122(1):49-60. doi: 10.1007/s00401-011-0831-1. Epub 2011 May 1. Acta Neuropathol. 2011. PMID: 21533854 Free PMC article.
-
M1 muscarinic acetylcholine receptor in Alzheimer's disease.Neurosci Bull. 2014 Apr;30(2):295-307. doi: 10.1007/s12264-013-1406-z. Epub 2014 Mar 3. Neurosci Bull. 2014. PMID: 24590577 Free PMC article. Review.
-
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.J Neurochem. 2021 Sep;158(6):1394-1411. doi: 10.1111/jnc.15471. Epub 2021 Aug 6. J Neurochem. 2021. PMID: 34272732 Free PMC article. Review.
-
Combined Effects of Intermittent Hypoxia and Amyloid Beta on Hippocampal Activity, Its Cholinergic Modulation, and Memory.Hippocampus. 2025 Jul;35(4):e70017. doi: 10.1002/hipo.70017. Hippocampus. 2025. PMID: 40495777 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical